Cargando…
SAT-516 A Severe Case of Pembrolizumab-Induced Thyroiditis
Pembrolizumab, a programmed death 1 (PD-1) inhibitor used for advanced malignancies, can be associated with thyroid dysfunction.(1-2) Specifically, thyroiditis occurs in nearly 2.3% of individuals.(2) The hyperthyroid phase is typically non-severe, requiring only beta blockers. Our case illustrates...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208842/ http://dx.doi.org/10.1210/jendso/bvaa046.1895 |